WSJ: Endo International is weighing bankruptcy option – Delaware Business Now

Endo Worldwide, a DuPont spin-off is taking a look at a chapter submitting because it faces a rising tide of opioid-related authorized actions, based on the Wall Road Journal reported.

The Delaware Valley-based firm is laboring underneath a heavy debt load whereas coping with lawsuits from governmental items arising from pharma firms promoting extra opioid drugs than wanted for official medical functions.

The authorized publicity has led to chapter filings for 2 different firms,  Purdue Pharma and Mallinckrodt. Endo, in contrast to its friends didn’t attain an total settlement on claims.

Endo, an organization that makes a speciality of ache drugs equivalent to Percocet, was bought by DuPont in 1997 to DuPont pharmaceutical managers who tapped into personal fairness financing. DuPont later moved its pharmaceutical operations right into a three way partnership with Merck and later exited the pharmaceutical enterprise.

The corporate, which went public in a inventory sale, grew quickly by way of demand for its merchandise and acquisitions.

Endo was first headquartered close to the Delaware line within the Concordville-Chadds Ford space and now has a U.S. headquarters in Malvern, PA. The corporate moved its international headquarters to Eire for tax causes.

Carol Ammon, its first CEO, post-DuPont, has been energetic in philanthropic actions in Delaware. Ammon retired in 2007.